126 related articles for article (PubMed ID: 18048092)
1. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
[TBL] [Abstract][Full Text] [Related]
2. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
[TBL] [Abstract][Full Text] [Related]
3. 4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression.
Sako T; Nakayama Y; Minagawa N; Inoue Y; Onitsuka K; Katsuki T; Tsurudome Y; Shibao K; Hirata K; Nagata N; Ohie S; Kohno K; Itoh H
In Vivo; 2005; 19(1):125-32. PubMed ID: 15796164
[TBL] [Abstract][Full Text] [Related]
4. The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer.
Shibata J; Murakami K; Aoyagi Y; Oie S; Hashimoto A; Suzuki K; Sano M; Wierzba TT; Yamada Y
Anticancer Res; 2000; 20(5B):3583-90. PubMed ID: 11131666
[TBL] [Abstract][Full Text] [Related]
5. 4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line.
Inoue Y; Nakayama Y; Sako T; Minagawa N; Abe Y; Nagato M; Kadowaki K; Katsuki T; Matsumoto K; Tsurudome Y; Shibao K; Hirata K; Nagata N
In Vivo; 2007; 21(2):381-7. PubMed ID: 17436592
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity.
Shibata J; Murakami K; Wierzba K; Aoyagi Y; Hashimoto A; Sano M; Toko T; Yamada Y
Anticancer Res; 2000; 20(5A):3169-76. PubMed ID: 11062739
[TBL] [Abstract][Full Text] [Related]
8. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
9. Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
Sakukawa R; Murakami K; Ikeda T; Yamada Y; Saiki I
Oncol Res; 1998; 10(6):287-93. PubMed ID: 9848099
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
11. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma.
Etter AL; Bassi I; Germain S; Delaloye JF; Tschopp J; Sordat B; Dupuis M
Gynecol Oncol; 2007 Oct; 107(1):14-21. PubMed ID: 17604087
[TBL] [Abstract][Full Text] [Related]
12. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma.
Saga Y; Ohwada M; Suzuki M; Konno R; Kigawa J; Ueno S; Mano H
Oncol Rep; 2008 Dec; 20(6):1299-303. PubMed ID: 19020706
[TBL] [Abstract][Full Text] [Related]
13. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
Gorai I; Nakazawa T; Miyagi E; Hirahara F; Nagashima Y; Minaguchi H
Gynecol Oncol; 1995 Apr; 57(1):33-46. PubMed ID: 7535723
[TBL] [Abstract][Full Text] [Related]
15. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.
Formelli F; Cleris L
Cancer Res; 1993 Nov; 53(22):5374-6. PubMed ID: 8221674
[TBL] [Abstract][Full Text] [Related]
16. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
Ghamande S; Hylander BL; Oflazoglu E; Lele S; Fanslow W; Repasky EA
Cancer Res; 2001 Oct; 61(20):7556-62. PubMed ID: 11606394
[TBL] [Abstract][Full Text] [Related]
17. A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells.
Oikawa T; Murakami K; Sano M; Shibata J; Wierzba K; Yamada Y
Jpn J Cancer Res; 2001 Nov; 92(11):1225-34. PubMed ID: 11714448
[TBL] [Abstract][Full Text] [Related]
18. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells.
Suzuki N; Aoki D; Tamada Y; Susumu N; Orikawa K; Tsukazaki K; Sakayori M; Suzuki A; Fukuchi T; Mukai M; Kojima-Aikawa K; Ishida I; Nozawa S
Gynecol Oncol; 2004 Nov; 95(2):290-8. PubMed ID: 15491748
[TBL] [Abstract][Full Text] [Related]
19. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo.
Chang HL; Su JH; Yeh YT; Lee YC; Chen HM; Wu YC; Yuan SS
Cancer Lett; 2008 Aug; 267(1):85-95. PubMed ID: 18430509
[TBL] [Abstract][Full Text] [Related]
20. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
Bodo J; Chovancova J; Hunakova L; Sedlak J
Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
